Project Oncology®

With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.

Multi-cancer early detection tests are designed to detect multiple cancers from a single blood test. Could these tests help address some of the most common limitations associated with current cancer screening methods, like a lack of adherence and access? Joining Dr. Jacob Sands to discuss how multi-cancer early detection tests work and their potential impact on cancer screening is Dr. Tom Beer, Adjunct Professor of Medicine at the OHSU Knight Cancer Institute and the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.

With the relaunch of the Cancer Moonshot initiative, implementing strategies to overcome disparities in cancer screening is critical to reducing the rate of cancer mortality. Dr. Charles Turck joins Dr. Mark Fendrick to explore these disparities, and discuss the role of multicancer detection tests.

Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!

Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.

Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.

Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.

New longer-term outcome data for chronic lymphocytic leukemia (CLL) has recently emerged with some interesting results. To dive into the key findings of these trials and other current CLL treatments available, Dr. Charles Turck is joined by Dr. Ehan Atallah, Professor of Medicine and the Section Head of Hematological Malignancies at the Medical College of Wisconsin Division of Hematology and Oncology.

A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.